Login
Companies $ENTX
$3.02 +$0.00 (0.0%) After hours
Entera Bio Ltd. logo

Entera Bio Ltd.

enterabio.com

What Do They Do?

Develops oral peptide tablets for patients with osteoporosis, hypoparathyroidism and metabolic disorders.

How Do They Make Money?

Revenue comes from research services under an agreement, with the services revenue counted over the agreement’s duration.

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $11.4M in FY2025.

Operating income, FY2025
−27450% of revenue
▼ −20% (Loss) vs FY2024 (−$9.6M, −5296%)
Net income, FY2025
−27236% of revenue
▼ −20% (Loss) vs FY2024 (−$9.5M, −5271%)
Free cash flow, FY2025
−17802% of revenue
▼ −10% (Loss) vs FY2024 (−$6.8M, −3769%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
vs $0 in Q3 FY2025
Net income
▼ −387% (Loss)
vs −$3.2M in Q3 FY2025

Shrinking. Revenue fell 93% in 4 years, from $571K in FY2021 to $42K in FY2025, about 48% a year.

Broader peptide programs The older report centers on oral PTH candidates and describes other peptides as early research; the latest details an oral metabolic-peptide collaboration and an oral tablet program for short bowel syndrome.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support